Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine.

ABSTRACT: Despite the great efforts for better treatment options for diffuse large B-cell lymphoma (DLBCL) (most common form of non-Hodgkin lymphoma, NHL) to treat and prevent relapse, it continues to be a challenge. Here, we present an overview of DLBCL and address the diagnostic assays and molecular techniques used in its diagnosis, role of biomarkers in detection, treatment of early and advanced stage DLBCL, and novel drug regimens. We discuss the significant biomarkers that have emerged as essential tools for stratifying patients according to risk factors and for providing insights into the use of more targeted and individualized therapeutics. We discuss techniques such as gene expression studies, including next-generation sequencing, which have enabled a more understanding of the complex pathog

SUBMITTER: Lodhi N 

PROVIDER: S-EPMC7646825 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature